Vistagen’s social anxiety disorder drug candidate has flunked another phase 3 trial. But, with a post hoc subpopulation analysis linking fasedienol to a nominally statistically significant improvement, the biotech plans to talk to the FDA about a path to approval built around a single future phase 3 study and confirmatory evidence from its broader PALISADE program.